stoxline Quote Chart Rank Option Currency Glossary
SELLAS Life Sciences Group, Inc. (SLS)
1.41  0.06 (4.44%)    05-30 15:52
Open: 1.34
High: 1.44
Volume: 440,731
Pre. Close: 1.35
Low: 1.34
Market Cap: 81(M)
Technical analysis
2024-05-30 3:17:27 PM
Short term     
Mid term     
Targets 6-month :  1.84 1-year :  2.15
Resists First :  1.58 Second :  1.84
Pivot price 1.4
Supports First :  1.29 Second :  1.12
MAs MA(5) :  1.37 MA(20) :  1.37
MA(100) :  1.07 MA(250) :  1.24
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  44.3 D(3) :  43.4
RSI RSI(14): 53.7
52-week High :  1.9 Low :  0.5
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ SLS ] has closed below upper band by 41.1%. Bollinger Bands are 57.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.37 - 1.38 1.38 - 1.39
Low: 1.3 - 1.31 1.31 - 1.32
Close: 1.34 - 1.35 1.35 - 1.36
Company Description

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.

Headline News

Wed, 22 May 2024
Can SELLAS Life Sciences Group (NASDAQ:SLS) Afford To Invest In Growth? - Yahoo Finance

Tue, 14 May 2024
SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Wed, 01 May 2024
SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in ... - GlobeNewswire

Wed, 01 May 2024
SELLAS reports promising AML treatment data By -

Fri, 19 Apr 2024
Sellas Life Sciences Group: A Lottery Ticket With An Estimated 6x Payout (NASDAQ:SLS) - Seeking Alpha

Thu, 28 Mar 2024
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 58 (M)
Shares Float 56 (M)
Held by Insiders 0.2 (%)
Held by Institutions 16.1 (%)
Shares Short 6,990 (K)
Shares Short P.Month 5,270 (K)
Stock Financials
EPS -1.35
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.25
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -174.3 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -31 (M)
Levered Free Cash Flow -30 (M)
Stock Valuations
PE Ratio -1.06
PEG Ratio 0
Price to Book value -5.68
Price to Sales 0
Price to Cash Flow -2.62
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android